Background CheckMate 9LA, a phase 3, randomized, open-label study in first-line advanced
non-small cell lung cancer (NSCLC), showed significantly improved overall survival (OS)
with nivolumab plus ipilimumab combined with 2 cycles of chemotherapy versus
chemotherapy alone (4 cycles). We present results for the Asian subpopulation enrolled in
Japan and China. Methods Patients aged≥ 18 years with treatment-naive, histologically
confirmed stage IV or recurrent NSCLC, Eastern Cooperative Oncology Group performance …

Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate
whether the addition of a limited course (two cycles) of chemotherapy to this combination
would further enhance the clinical benefit. Methods This randomised, open-label, phase 3
trial was done at 103 hospitals in 19 countries. Eligible patients were aged 18 years or older
with treatment-naive, histologically confirmed stage IV or recurrent NSCLC, and an Eastern …